Institutional investors purchased a net $543.0 thousand shares of NLNK during the quarter ended September 2014. This may signal that the smart money is gaining interest in this company as the 53.47% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
POINTSTATE CAPITAL LP Bought 325.0 Thousand shares of NewLink Genetics Corp